CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
AVM Biotechnology Inc
Acerta Pharma BV
Cellectar Biosciences, Inc.
Pierre Fabre Medicament
Pierre Fabre Medicament
Pfizer
AbbVie
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Novartis
Viracta Therapeutics, Inc.
Juno Therapeutics, a Subsidiary of Celgene
Zhejiang DTRM Biopharma
Oncternal Therapeutics, Inc
Celgene
Astex Pharmaceuticals, Inc.
OriCell Therapeutics Co., Ltd.
Amgen
AO GENERIUM
Nordic Nanovector
Celgene
Atara Biotherapeutics
Oncternal Therapeutics, Inc
Celularity Incorporated
Takeda
Vifor Pharma
miRagen Therapeutics, Inc.
Beijing Immunochina Medical Science & Technology Co., Ltd.
Incyte Corporation
Spectrum Pharmaceuticals, Inc
Gilead Sciences
AbbVie
Merck Sharp & Dohme LLC
Takeda
miRagen Therapeutics, Inc.
Amgen Research (Munich) GmbH
LEO Pharma
Nordic Nanovector
Eisai Inc.
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Novartis
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.